[go: up one dir, main page]

CA3010862A1 - Methodes et dispositifs pour le traitement de troubles oculaires posterieurs avec l'aflibercept et d'autres substances biologiques - Google Patents

Methodes et dispositifs pour le traitement de troubles oculaires posterieurs avec l'aflibercept et d'autres substances biologiques Download PDF

Info

Publication number
CA3010862A1
CA3010862A1 CA3010862A CA3010862A CA3010862A1 CA 3010862 A1 CA3010862 A1 CA 3010862A1 CA 3010862 A CA3010862 A CA 3010862A CA 3010862 A CA3010862 A CA 3010862A CA 3010862 A1 CA3010862 A1 CA 3010862A1
Authority
CA
Canada
Prior art keywords
antibody
vegf
drug
aflibercept
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3010862A
Other languages
English (en)
Inventor
Samirkumar PATEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clearside Biomedical Inc
Original Assignee
Clearside Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clearside Biomedical Inc filed Critical Clearside Biomedical Inc
Publication of CA3010862A1 publication Critical patent/CA3010862A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des méthodes et des dispositifs pour le traitement de la dégénérescence maculaire liée à l'âge (DMLA) humide, la néovascularisation choroïdienne (CNV), la DMLA humide associée à la CNV et/ou la DMLA humide associée à l'occlusion veineuse rétinienne (RVO) chez un sujet humain qui en a besoin. Selon certains aspects, les dispositifs décrits dans la présente description comprennent un récipient de médicament délimitant une lumière conçue pour contenir un médicament, une partie terminale distale du récipient de médicament comprenant une partie d'accouplement conçue pour être accouplée amovible à un ensemble aiguille, une partie terminale proximale du récipient de médicament comprenant un rebord et un épaulement longitudinal ; un ensemble piston comprenant une partie terminale distale disposée mobile à l'intérieur de la lumière du récipient de médicament ; et une poignée accouplée à une partie terminale proximale de l'ensemble piston.
CA3010862A 2016-01-08 2017-01-09 Methodes et dispositifs pour le traitement de troubles oculaires posterieurs avec l'aflibercept et d'autres substances biologiques Abandoned CA3010862A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662276543P 2016-01-08 2016-01-08
US62/276,543 2016-01-08
US201662324708P 2016-04-19 2016-04-19
US62/324,708 2016-04-19
PCT/US2017/012757 WO2017120601A1 (fr) 2016-01-08 2017-01-09 Méthodes et dispositifs pour le traitement de troubles oculaires postérieurs avec l'aflibercept et d'autres substances biologiques

Publications (1)

Publication Number Publication Date
CA3010862A1 true CA3010862A1 (fr) 2017-07-13

Family

ID=59274052

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3010862A Abandoned CA3010862A1 (fr) 2016-01-08 2017-01-09 Methodes et dispositifs pour le traitement de troubles oculaires posterieurs avec l'aflibercept et d'autres substances biologiques

Country Status (9)

Country Link
EP (1) EP3400014A1 (fr)
JP (1) JP2019501200A (fr)
KR (1) KR20180101488A (fr)
CN (1) CN108778330A (fr)
AU (1) AU2017206114A1 (fr)
BR (1) BR112018013805A2 (fr)
CA (1) CA3010862A1 (fr)
MX (1) MX2018008469A (fr)
WO (1) WO2017120601A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
BR112013009205A2 (pt) 2010-10-15 2016-07-26 Iscience Interventional Corp dispositivo para colocação na esclera de um olho, método para acessar o espaço supracoroidal de um olho, para acessar o espaço subretinal de um olho e para colocar um orifício dentro de um trato escleral em um olho.
CA3240136A1 (fr) 2012-11-08 2014-05-15 Clearside Biomedical, Inc. Methodes et dispositifs pour le traitement de maladies oculaires chez les sujets humains
SG10201702674PA (en) 2013-05-03 2017-06-29 Clearside Biomedical Inc Apparatus and methods for ocular injection
EP3003454B1 (fr) 2013-06-03 2020-01-08 Clearside Biomedical, Inc. Appareil pour une administration de médicament à l'aide de multiples réservoirs
CA2918419C (fr) 2013-07-23 2022-05-03 Novaliq Gmbh Compositions d'anticorps stabilisees
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2017055454A1 (fr) 2015-09-30 2017-04-06 Novaliq Gmbh Composés semi-fluorés et leurs compositions
WO2017117464A1 (fr) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Anticorps et conjugués de ceux-ci
MA44873A (fr) 2016-04-15 2019-03-13 Univ Pennsylvania Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative
JP2019514581A (ja) 2016-05-02 2019-06-06 クリアサイド バイオメディカル，インコーポレイテッド 眼の薬物送達のためのシステムおよび方法
IL264764B2 (en) 2016-08-12 2024-02-01 Clearside Biomedical Inc Devices and methods for adjusting the insertion depth of a drug administration needle
WO2018204515A1 (fr) 2017-05-02 2018-11-08 Georgia Tech Research Corporation Procédés d'administration ciblée de médicament au moyen d'une microaiguille
KR20200060456A (ko) * 2017-09-27 2020-05-29 리젠엑스바이오 인크. 완전-인간 번역후 변형된 항-VEGF Fab를 이용한 안구 질환의 치료
CA3086522A1 (fr) * 2017-12-20 2019-06-27 Angex Pharmaceutical, Inc. Composes de carbamate et d'uree utilises comme inhibiteurs de multikinases
CN108030783A (zh) * 2017-12-27 2018-05-15 广东众生药业股份有限公司 乐伐替尼在制备防治黄斑变性的药物中的用途
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
NZ770284A (en) 2018-05-10 2025-11-28 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations
CN110693886B (zh) * 2018-07-09 2022-12-06 天津医科大学 防治脑海绵状血管畸形病变的药物
LT3897595T (lt) * 2018-12-20 2023-04-25 Laboratoires Thea Maistinė oftalmologinė kompozicija, skirta gydyti tinklainės patologijoms su neovaskuliniu komponentu
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
KR20200101160A (ko) * 2019-02-19 2020-08-27 전남대학교산학협력단 리보세라닙을 포함하는 안구 신생혈관 억제용 약학 조성물 및 이를 이용한 안구 신생혈관 억제 방법
CN113966236A (zh) * 2019-04-03 2022-01-21 再生生物股份有限公司 眼睛病状的基因疗法
CN110522909B (zh) * 2019-09-30 2024-02-20 安徽省立医院 一种协同增强抗her2阳性肿瘤效果的药物组合
WO2021072265A1 (fr) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Procédés de traitement d'un trouble oculaire
JP2023500385A (ja) * 2019-11-11 2023-01-05 シーストーン・ファーマシューティカルズ・（スージョウ）・カンパニー・リミテッド 医薬組合せ物およびその使用
MX2022006439A (es) * 2019-12-19 2022-07-19 Active Biotech Ab Compuestos para el tratamiento de enfermedades oculares asociadas con la vascularizacion excesiva.
EP4106755A4 (fr) * 2020-02-19 2024-03-27 Clearside Biomedical, Inc. Compositions comprenant de l'axitinib et méthodes de traitement de troubles oculaires
US20230241080A1 (en) * 2020-06-15 2023-08-03 Arturo Santos Triamcinolone acetonide-loaded liposomes topical ophthalmic formulations as primary therapy for macular edema secondary to branch retinal vein occlusion
EP4185318B1 (fr) * 2021-05-17 2025-09-03 Regeneron Pharmaceuticals, Inc. Régimes d'antagoniste de vegf à dose élevée et étendu pour le traitement de troubles oculaires angiogéniques
CN113546176B (zh) * 2021-06-30 2024-03-15 南通大学 一种特异性用于抑制眼内血管新生药物合成方法
CN116087525B (zh) * 2022-11-16 2025-10-28 东南大学 一种即时检测Tau蛋白的微腔结构高灵敏SERS芯片的制备方法
CN118356501A (zh) * 2023-01-19 2024-07-19 百奥泰生物制药股份有限公司 一种复方制剂及其应用
WO2024167694A2 (fr) * 2023-02-06 2024-08-15 Celularity Inc. Matrices extracellulaires placentaires pour l'administration oculaire d'agents thérapeutiques ophtalmiques
JP2025003405A (ja) * 2023-06-23 2025-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 眼内血管新生性疾患の治療のための、ｖｅｇｆアンタゴニストの延長された高用量レジメン

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012262921A1 (en) * 2011-05-27 2013-11-21 Novartis Ag Method of treating vision disorders
CA2865132A1 (fr) * 2012-02-22 2013-08-29 Trustees Of Tufts College Compositions et procedes pour administration oculaire d'un agent therapeutique
CA3240136A1 (fr) * 2012-11-08 2014-05-15 Clearside Biomedical, Inc. Methodes et dispositifs pour le traitement de maladies oculaires chez les sujets humains
CA2933900A1 (fr) * 2013-12-20 2015-06-25 Georgia Tech Research Corporation Preparations et procedes servant a introduire de maniere ciblee des agents therapeutiques dans l'ƒil
EP3157463A4 (fr) * 2014-06-17 2018-02-21 Clearside Biomedical, Inc. Procédés et dispositifs de traitement de troubles oculaires postérieurs

Also Published As

Publication number Publication date
MX2018008469A (es) 2018-11-09
BR112018013805A2 (pt) 2018-12-11
CN108778330A (zh) 2018-11-09
JP2019501200A (ja) 2019-01-17
WO2017120601A1 (fr) 2017-07-13
AU2017206114A1 (en) 2018-08-02
EP3400014A1 (fr) 2018-11-14
KR20180101488A (ko) 2018-09-12

Similar Documents

Publication Publication Date Title
US12350261B2 (en) Methods and devices for the treatment of ocular diseases in human subjects
KR102511477B1 (ko) 안구 후부 질환을 치료하기 위한 방법 및 디바이스
CA3010862A1 (fr) Methodes et dispositifs pour le traitement de troubles oculaires posterieurs avec l'aflibercept et d'autres substances biologiques
HK40041836A (en) Methods for the treatment of ocular disease in human subjects
HK40041836B (en) Methods for the treatment of ocular disease in human subjects
HK1213192B (en) Methods for the treatment of ocular disease in human subjects
HK1235263A1 (en) Methods and devices for treating posterior ocular disorders

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210831

FZDE Discontinued

Effective date: 20210831